Top

05-03-2025 | Metastasis | Research Article

Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer

Authors: Junwei Yin, Yongli Zhao, Junping Yin, Shanshan Yang

Published in: Clinical and Translational Oncology

Abstract

Background

Liver metastases from colorectal cancer are a common and serious complication that significantly impacts patient survival. The aim of this study is to investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of liver metastases from colorectal cancer.

Methods

A retrospective analysis was conducted on 120 patients with liver metastases from colorectal cancer who were treated in our hospital from January 2018 to January 2023. The patients were divided into two groups based on the treatment they received: the TACE group (n = 60) and the TACE combined with RFA group (n = 60). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups, and treatment-related adverse effects were recorded.

Results

The TACE combined with RFA group showed significantly better OS (22 months vs. 18 months) and PFS (13 months vs. 10 months) compared to the TACE alone group (P < 0.05). The ORR in the TACE combined with RFA group was 61.7%, significantly higher than 40% in the TACE alone group (P < 0.05). The DCR showed no significant difference between the two groups, with 86.7% (52/60) in the TACE combined with RFA group and 78.3% (47/60) in the TACE alone group (P > 0.05). There were no significant differences in treatment-related adverse effects between the two groups (P > 0.05).

Conclusion

These findings suggest that TACE combined with RFA may offer a potential option for improving OS, PFS, and ORR in patients with liver metastases from colorectal cancer, without increasing significant adverse effects, setting a new potential standard of care in the treatment of this disease.

Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, et al. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol. 2020;11(10):761–808. https://doi.org/10.5306/wjco.v11.i10.761.CrossRefPubMedPubMedCentral

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85. https://doi.org/10.1001/jama.2021.0106.CrossRefPubMed

Zou YW, Ren ZG, Sun Y, Liu ZG, Hu XB, Wang HY, et al. The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2023;22(1):54–63. https://doi.org/10.1016/j.hbpd.2022.08.004.CrossRefPubMed

Ning Z, Zhu Y, Xie L, Yan X, Hua Y, Meng Z. Exploring the efficacy and safety of drug-eluting beads transarterial chemoembolization in pancreatic cancer liver metastasis. Br J Radiol. 2024;97(1157):1010–5. https://doi.org/10.1093/bjr/tqae059.CrossRefPubMed

Li H, Zhang X, Zhao W, Cai F, Qin J, Tian J. Efficacy of CalliSpheres(R) microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis. BMC Cancer. 2023;23(1):970. https://doi.org/10.1186/s12885-023-11350-y.CrossRefPubMedPubMedCentral

Larijani RS, Ravari NS, Goodarzi N, Akhlaghpour S, Larijani SS, Rouini MR, et al. Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment. J Drug Deliv Sci Technol. 2022;77:103905.CrossRef

Yuan G, Liu Z, Wang W, Liu M, Xu Y, Hu W, et al. Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma. J Nanobiotechnol. 2023;21(1):68. https://doi.org/10.1186/s12951-023-01820-7.CrossRef

Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer. 2021;10(6):539–44. https://doi.org/10.1159/000519749.CrossRefPubMedPubMedCentral

Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Critical Rev Oncol/Hematol. 2011;80(1):40–53. https://doi.org/10.1016/j.critrevonc.2010.10.005.CrossRef

10.

Rizzo A, Ricci AD, Brandi G. Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: an update. J Personal Med. 2022;12(11):1788. https://doi.org/10.3390/jpm12111788.CrossRef

11.

Geoghegan R, Ter Haar G, Nightingale K, Marks L, Natarajan S. Methods of monitoring thermal ablation of soft tissue tumors - A comprehensive review. Med Phys. 2022;49(2):769–91. https://doi.org/10.1002/mp.15439.CrossRefPubMed

12.

Chevallier O, Zhao K, Marinelli B, Yarmohammadi H. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma. Chinese Clini Oncol. 2023;12(2):17.CrossRef

13.

Bannerman D, Wan W. Multifunctional microbeads for drug delivery in TACE. Expert Opin Drug Deliv. 2016;13(9):1289–300.CrossRefPubMed

14.

Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist. 2019;24(10):e990–1005.CrossRefPubMedPubMedCentral

15.

Wang H, Liu B, Long H, Zhang F, Wang S, Li F. Clinical study of radiofrequency ablation combined with TACE in the treatment of breast cancer with liver metastasis. Oncol Let. 2017;14(3):2699–702. https://doi.org/10.3892/ol.2017.6483.CrossRef

16.

Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). European Radiol. 2006;16:661–9.CrossRef

17.

Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72(2):288–306. https://doi.org/10.1016/j.jhep.2019.09.026.CrossRefPubMed

18.

Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24:3669–76.CrossRefPubMedPubMedCentral

19.

Balli HT, Aikimbaev K. Intra-arterial Chemotherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer in the Middle East 2021:171–187 https://doi.org/10.1007/978-3-030-78737-0_10

20.

Nelson K, Jutric Z, Georgiades C. Physics and physiology of thermal ablations. Image-guided interventions in oncology: an interdisciplinary approach. 2020:1–13 https://doi.org/10.1007/978-3-030-48767-6_1

21.

Xie Y, Lyu T, Song L, Tong X, Wang J, Zou Y. TACE-assisted multi-image guided radiofrequency ablation for the treatment of single hepatocellular carcinoma </= 5 cm: a retrospective study. Front Oncol. 2024;14:1347675.CrossRefPubMedPubMedCentral

22.

Wang XH, Duan WB, Liang W, Li H, Xie XY, Li SQ, et al. Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort study. EClinicalMedicine. 2023;56:101816.CrossRefPubMedPubMedCentral

23.

Uhlig J, Lukovic J, Dawson LA, Patel RA, Cavnar MJ, Kim HS. Locoregional therapies for colorectal cancer liver metastases: options beyond resection. Am Soc Clin Oncol Educ Book. 2021;41:133–46.CrossRefPubMed

24.

Jing C, Li J, Yuan C, Hu C, Ma L, Zheng J, et al. Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study. Eur J Radiol. 2024;178:111619.CrossRefPubMed

25.

Zhang K, Mu L, Ren Y, Jiang T. Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study. Eur J Radiol. 2023;167:111092.CrossRefPubMed

26.

Cha DI, Lee MW, Hyun D, Ahn SH, Jeong WK, Rhim H. Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma infeasible for ultrasound-guided percutaneous radiofrequency ablation: a comparative study with general ultrasound-guided radiofrequency ablation outcomes. Cancers (Basel). 2023;15(21):5193. https://doi.org/10.3390/cancers15215193.CrossRefPubMed

27.

Guo JY, Zhao LL, Cai HJ, Zeng H, Mei WD. Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer. World J Gastrointest Surg. 2024;16(6):1756–64. https://doi.org/10.4240/wjgs.v16.i6.1756.CrossRefPubMedPubMedCentral

28.

Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andre F, Roy-Chowdhuri S, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617–35. https://doi.org/10.1016/j.cell.2024.02.041.CrossRefPubMedPubMedCentral

29.

Gallagher A, Shersher V, Mortimer D, Truby H, Haines T. The cost-effectiveness of adjunctive lifestyle interventions for the management of cancer: a systematic review. Appl Health Econ Health Policy. 2023;21(2):225–42.CrossRefPubMed

Title: Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer
Authors: Junwei Yin
Yongli Zhao
Junping Yin
Shanshan Yang
Publication date: 05-03-2025
Publisher: Springer International Publishing
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-025-03879-0

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Podcast | Sexual health in older age

Springer Medicine

Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer

Abstract

Background

Methods

Results

Conclusion

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Podcast | Sexual health in older age

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma